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Abstract
Atopic dermatitis (AD) is a common, chronic skin disorder that can significantly impact the quality of life of
affected individuals as well as their families. Although the pathogenesis of the disorder is not completely
understood, it appears to result from the complex interplay between defects in skin barrier function, environmental
and infectious agents, and immune abnormalities. There are no specific diagnostic tests for AD; therefore, the
diagnosis is based on specific clinical criteria that take into account the patient’s history and clinical manifestations.
Successful management of the disorder requires a multifaceted approach that involves education, optimal skin care
practices, anti-inflammatory treatment with topical corticosteroids and/or topical calcineurin inhibitors (TCIs), the
use of first-generation antihistamines to help manage sleep disturbances, and the treatment of skin infections.
Systemic corticosteroids may also be used, but are generally reserved for the acute treatment of severe flare-ups.
Topical corticosteroids are the first-line pharmacologic treatments for AD, and evidence suggests that these agents
may also be beneficial for the prophylaxis of disease flare-ups. Although the prognosis for patients with AD is
generally favourable, those patients with severe, widespread disease and concomitant atopic conditions, such as
asthma and allergic rhinitis, are likely to experience poorer outcomes.
Introduction
Atopic dermatitis (AD) is a chronic, highly pruritic
(itchy) inflammatory skin disease, and is one of the
most common skin disorders in children [1]. The disor-
der results in significant morbidity and adversely affects
quality of life [2]. Not only are patients affected by the
social stigma of a visible skin condition, but the intense
itching characteristic of the disease often leads to signifi-
cant sleep disturbances. In addition, management of the
condition necessitates the frequent application of emolli-
ents (agents that soothe, moisturize and soften the skin)
and topical medications, as well as physician visits. AD
also poses a significant economic burden with an esti-
mated annual cost in Canada of $1.4 billion [3].
Evidence suggests that AD is a cutaneous manifesta-
tion of a systemic disorder that also gives rise to other
atopic conditions. In fact, AD is often the initial step in
the “atopic march” (the sequential development of aller-
gic disease manifestations during early childhood),
which leads to asthma and/or allergic rhinitis in the
majority of afflicted patients [4].
New insights into AD suggest that both structural
abnormalities of the skin and immune dysregulation
play important roles in the pathophysiology of the dis-
ease. Therefore, optimal management of AD requires a
multifaceted approach aimed at healing and protecting
the skin barrier and addressing the complex immuno-
pathogenesis of the disease [5]. This article provides an
overview of current literature related to the epidemiol-
ogy, pathophysiology, diagnosis, and appropriate man-
agement of AD.
Pathophysiology
The pathogenesis of AD is not completely understood,
however, the disorder appears to result from the com-
plex interaction between defects in skin barrier function,
immune abnormalities, and environmental and infec-
tious agents. Skin barrier abnormalities appear to be
associated with mutations within the filaggrin gene,
which encodes a structural protein essential for skin
barrier formation. The skin of individuals with AD has
also been shown to be deficient in ceramides (lipid
molecules) as well as antimicrobial peptides such as
cathelicidins, which represent the first-line of defense
against many infectious agents. These skin barrier
abnormalities lead to transepidermal water loss (passage
of water from inside the body through the epidermal
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increased penetration of allergens and microbes into the
skin. The infectious agent most often involved in AD is
Staphylococcus aureus (S. aureus), which colonizes in
approximately 90% of AD patients. Defective innate
immune responses also appear to contribute to
increased bacterial and viral infections in patients with
AD. This interplay of factors leads to T-cell responses
in the skin (initially a predominantly T helper-2 [Th2]
response and later a predominantly Th1 response) with
resultant release of chemokines and proinflammatory
cytokines (e.g., interleukin [IL]-4, 5 and tumour necrosis
factor) that promote immunoglobulin E (IgE) produc-
tion and systemic inflammatory responses, leading to
pruritic inflammation of the skin [6-8].
Epidemiology
The prevalence of AD has increased over the past 30
years. It is currently estimated that 10-20% of children
and 1-3% of adults in developed countries are affected
by the disorder [9]. AD often starts in early infancy;
approximately 45% of all cases begin within the first 6
months of life, 60% during the first year, and 85% before
5 years of age. Up to 70% of these children outgrow the
disorder before adolescence [10].
As mentioned earlier, children with AD are at high
risk of developing asthma and allergic rhinitis. Of those
who develop AD before the age of 2, 50% will develop
asthma during subsequent years. Furthermore, those
children with AD who develop asthma and allergic rhi-
nitis are more likely to have severe disease [6].
Diagnosis
There are no specific diagnostic tests for AD. Diagnosis
of the disorder is based on specific criteria that take
into account the patient’s history and clinical manifesta-
tions. Although various diagnostic criteria for AD have
been proposed and validated, the application of many of
these criteria is time consuming and necessitates inva-
sive testing. Table 1 provides simplified criteria pro-
posed by Williams et al. that are easy to use, do not
require invasive testing, and have been shown to have a
high sensitivity and specificity for the diagnosis of AD
[11-14]. Using these criteria, the diagnosis of AD
requires the presence of an itchy skin condition (or par-
ental/caregiver reports of scratching or rubbing in a
child) plus three or more minor criteria, which vary
depending on the patient’s age.
The clinical manifestations of AD vary with age (see
Table 2). In infants, the scalp, face, neck, trunk and
extensor (outer) surfaces of the extremities are generally
affected, while the diaper area is usually spared. Chil-
dren typically have involvement of the flexural surfaces
of the extremities (i.e., fold/bend at the elbow and back
of the knee), neck, wrists and ankles (see Figure 1). In
adolescence and adulthood, the flexural surfaces of the
extremities, hands and feet are usually affected (see Fig-
ure 2). Regardless of age, the itching associated with AD
generally continues throughout the day and worsens at
night, leading to sleep loss and substantial impairments
in quality of life [2].
It is often difficult to differentiate AD from other skin
conditions (e.g., seborrheic dermatitis, contact dermati-
tis, psoriasis, scabies); however, a family history of atopy
and the distribution of lesions are helpful in making the
diagnosis in many cases. Psoriasis, for example, usually
affects the extensor rather than flexural surfaces, and
often involves the fingernails, palms of the hands and
soles of the feet. Seborrheic dermatitis typically involves
the diaper area in infants and the face in adults (e.g.,
sides of the nose, eyebrows, external ear canal). Further-
more, unlike AD, a family history of atopic disease is
uncommon in patients with seborrheic or contact der-
matitis. Scabies is generally associated with the presence
of pustules on the palms, soles, genitalia and between
the fingers. Other conditions that need to be considered
Table 1 Diagnostic criteria for AD. [11-13]
Major criteria:
Patient must have:
￿ An itchy skin condition (or parental/caregiver report of scratching or
rubbing in a child)
Minor criteria:
Plus three or more of the following minor criteria:
Older children/adults:
￿ History of itchiness in skin creases (e.g., folds of elbows, behind the
knees, front of ankles, around the neck)
￿ Personal history of asthma or allergic rhinitis
￿ Personal history of general dry skin in the last year
￿ Visible flexural dermatitis (i.e., in the bends or folds of the skin at the
elbow, knees, wrists, etc.)
￿ Onset under age 2 years
Children <4 years:*
￿ History of itching of the cheeks
￿ History of atopic disease in a first-degree relative
￿ Eczema of cheeks, forehead and outer limbs
* Early onset not always diagnostic in children under 4 years of age.
Table 2 Clinical manifestations of AD
Infants (0-2 years)
￿ Extensor surfaces of extremities
￿ Face (forehead, cheeks, chin)
￿ Neck
￿ Scalp
￿ Trunk
Childhood (2 years to puberty)
￿ Flexural surfaces of extremities
￿ Neck
￿ Wrists, ankles
Adolescence/adulthood
￿ Flexural surfaces of extremities
￿ Hands, feet
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nutritional deficiencies, malignancies and immunodefi-
ciency syndromes that are associated with skin manifes-
tations (see Table 3) [6,15].
Allergy assessment
The exact role of foods and aeroallergens in the patho-
genesis and exacerbation of AD is controversial.
Although most patients with AD demonstrate specific
IgE antibodies to foods and/or aeroallergens on skin
prick testing (SPT) and measurements of serum-specific
IgE levels, their clinical significance remains unclear.
[6,16] In other words, while a positive SPT or serum
specific IgE test indicates sensitization to a particular
allergen, this does not prove clinical hypersensitivity or
causation.
In clinical studies, approximately 35% of children with
moderate-to-severe AD have been found to have con-
tributory food allergies [16]. In general, the younger the
patient and the more severe the AD, the more likely it
is that food allergens may be responsible for exacerbat-
ing the disease. In contrast, food allergies appear to
have little, if any, role in adult AD [6].
Random testing or screening to food allergens is not
recommended as this may lead to unnecessary and inap-
propriate dietary restrictions in patients with AD. There-
fore, the decision to perform allergy testing to foods should
be based on disease severity and whether or not the
patient’s history is highly suggestive of food allergies [16].
Exposure to aeroallergens such as house dust mites,
animal dander, pollen and moulds can exacerbate AD in
some patients. In these cases, identification of sensitiza-
tion by SPT may be useful. If sensitization is established,
and the history suggests a causative role in worsening
AD, then specific avoidance measures should be consid-
ered since removal of the allergen from the patient’s
environment may improve the symptoms of AD. Atopy
patch testing is still considered investigational in
patients with AD because there are no standardized
methods of application or test interpretation. However,
patch tests may be useful for excluding a diagnosis of
concurrent contact dermatitis [6].
Treatment
The treatment of AD should be directed at limiting itch-
ing, repairing the skin and decreasing inflammation
when necessary. Therefore, the successful management
of AD requires a multifaceted approach that involves
patient and caregiver education, optimal skin care prac-
tices, anti-inflammatory treatment with topical corticos-
teroids (first-line) and/or topical calcineurin inhibitors
(TCIs), the use of first-generation antihistamines to help
manage sleep disturbances, and the treatment of skin
infections. Systemic corticosteroids may also be consid-
ered in severe cases that cannot be controlled with
appropriate skin care and topical therapy [1,6,17,18].
A simplified, stepwise algorithm for the treatment of
AD is provided in Figure 3. Physicians should monitor
patient progress and disease course regularly and evalu-
ate the efficacy and tolerability of therapy. Follow-up
evaluations should include an assessment of medication
use (e.g., type, quantity applied, refills made, etc.), which
allows the physician to gauge compliance and medica-
tion risks [1,18].
Figure 1 Atopic dermatitis (AD) of the flexural surfaces of the
extremities.
(a)
(b)
Figure 2 Atopic dermatitis (AD) of the hands (a) and feet (b)
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For optimal disease management, patients and/or their
caregivers should be educated about the chronic nature
of the disease, the need for continued adherence to
proper skin care practices, and the appropriate use and
application of topical therapies. Time spent educating
patients and caregivers has been shown to have a posi-
tive effect on disease outcomes. Patients should also be
provided with written instructions/information on
appropriate medication use, skin care and flare manage-
ment to reinforce learning. [1,6,17,18]
Skin care principles
A key feature of AD management is appropriate daily
skin care. Bathing once or twice daily (depending on the
severity of AD) in warm water for 10-15 minutes is
recommended to help hydrate and cleanse the skin,
assist in the debridement of infected skin, and improve
the penetration of topical therapies. Moisturizing
cleansers are recommended while highly fragranced
soaps should be avoided as they may irritate the skin.
After bathing, the patient’ss k i ns h o u l db ep a t t e dd r y
with a towel (so it remains slightly wet) and moisturi-
zers and emollients (e.g., petroleum jelly, Eucerin,
mineral oil, baby oil) should be applied liberally to help
prevent moisture loss and drying of the skin.
Topical corticosteroids
Topical corticosteroids are the first-line pharmacologic
treatments for AD. These agents effectively control ato-
pic flares through their anti-inflammatory, antiprolifera-
tive, and immunosuppressive actions. Numerous topical
corticosteroids are available in Canada, ranging from
low to high potency, and most of these agents are avail-
able in varying concentrations, preparations and doses
(see Table 4). Topical corticosteroids are applied to the
red, inflamed areas on the skin before the use of emolli-
ents. Some patients have inadvertently reversed the
order, which significantly reduces the benefits of the
topical corticosteroid.
There is limited clinical trial data to assist in choosing
a corticosteroid. Ointment preparations are generally
preferred over creams as they provide more uniform
coverage and penetration. Also, the least potent prepara-
tion required to control AD (particularly in sensitive
areas such as the face, neck, groin and underarms)
should be utilized and, when possible, therapy should be
stopped for short periods to reduce the risk of local and
systemic adverse events. Often, a low-potency prepara-
tion, such as hydrocortisone acetate 1% or equivalent, is
used for the face. Common local side effects of long-
term topical corticosteroid use include striae (stretch
marks), petechiae (small red/purple spots), telangiectasia
(small, dilated blood vessels on the surface of the skin),
skin thinning, atrophy and acne; however, these effects
are uncommon with low or moderate potency prepara-
tions. Systemic side effects with topical corticosteroid
use are rare, but may include growth retardation in chil-
dren, reduced bone density and hypothalamic-pituitary-
adrenal axis suppression [1,6,18].
Evidence also suggests that topical corticosteroids may
be beneficial for the prophylaxis of AD flares. Studies
have found that, after AD is stabilized, the addition of
Table 3 Differential diagnosis of AD
Other skin conditions
￿ Contact dermatitis
￿ Seborrheic dermatitis
￿ Psoriasis
Infections
￿ Scabies
￿ Impetigo
Metabolic and nutritional deficiencies
￿ Phenylketonuria
￿ Zinc deficiency
Immunodeficiency syndromes with skin manifestations
￿ Wiskott-Aldrich syndrome
￿ Severe combined immunodeficiency syndrome with Omenn’s syndrome
￿ Immune dysregulation, polyendocrinopathy, enteropathy, X-linked
￿ Graft vs. host disease
￿ Dermatitis herpetiformis
Malignancies
￿ T-cell lymphoma
Adjuvant therapy
for:
Bacterial infections: Oral 
and/or topical antibiotics;
diluted bleach baths
Viral infections: antiviral 
therapy
Sleep disturbances: first-
generation sedating
antihistamines 
Systemic 
corticosteroids
Topical calcineurin inhibitors
Topical corticosteroids
Skin care 
x Regular bathing
x Regular, liberal use of emollients/moisturizers
Education
x Chronic nature of the disease
x Importance of treatment adherence
x Appropriate use and application of topical 
therapies
Figure 3 A simplified, stepwise algorithm for the treatment of
AD
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ment) to maintenance treatment with emollients signifi-
cantly reduces the risk of relapses in both pediatric and
adult subjects [19-21]. A recent study also found that
twice-weekly methylprednisolone (0.1% cream) plus
emollients significantly reduces the risk of relapse and
improves overall patient status [22].
Topical calcineurin inhibitors (TCIs)
TCIs are immunosuppressant agents that have also been
shown to be effective for the treatment of AD. Two
TCIs — pimecrolimus (Elidel) and tacrolimus (Protopic)
— are currently approved in Canada for the second-line,
intermittent treatment of immunocompetent patients 2
years of age and older with moderate-to-severe AD.
Given the highs costs of these agents and the fact that
their long-term safety is not fully known, they are gener-
ally reserved for patients with persistent disease and/or
frequent flares that would require continuous topical
corticosteroid treatment, or in patients severely affected
in sensitive skin areas (e.g., around the eyes, face, neck
and genitals) where systemic absorption and the risk of
skin atrophy with topical corticosteroids are of particu-
lar concern [1,6,18].
The most common local adverse effects of TCIs are
skin burning and irritation. Although a causal link has
not been established, rare cases of skin malignancy and
lymphoma have also been reported in patients using
these agents. Therefore, both Health Canada and the
Food and Drug Administration (FDA) recommend cau-
tion when prescribing TCIs. Long-term use should be
avoided and patients using these agents should be coun-
seled on appropriate sun protection [1,6,18,23].
Antihistamines
Although first-generation antihistamines (e.g., hydroxy-
zine, diphenhydramine, chlorpheniramine) do not
directly affect the itching associated with AD, the seda-
tive effects of these agents have been found to help
improve sleep in patients with AD [1,6]. Therefore,
these agents may be considered for the short-term
adjuvant treatment of patients experiencing atopic flare-
ups who have difficulty sleeping or who scratch regu-
larly while sleeping. However, daytime use of first-gen-
eration antihistamines should be avoided given their
sedative properties. Non-sedating second-generation
antihistamines appear to have limited value in patients
with AD. However, these agents may provide some
modest benefits in patients with allergic triggers [1,6].
Treatment of skin infections
As mentioned earlier, the skin of patients with AD is
often heavily colonized with S. aureus, even at unin-
volved sites. To avoid the development of bacterial resis-
tance, short-term topical and/or oral antibiotic therapy
is therefore recommended when an overt secondary bac-
terial infection is present. Appropriate systemic antibio-
tics are indicated for widespread secondary infection,
and first- or second-generation cephalosporins or peni-
cillins for 7 to 10 days are usually effective in managing
the infection. Because erythromycin-resistant organisms
are common in patients with AD, macrolides are less
useful alternatives [6,15].
Patients with AD are also prone to recurrent viral
infections. Eczema herpeticum (a severe disseminated
herpes infection that generally occurs at sites of skin
damage; also known as Kaposi’s varicelliform eruption)
is a serious risk in patients with widespread AD and
may be easily misdiagnosed as a bacterial superinfection.
Patients with the condition will require systemic anti-
viral treatment with acyclovir or other antiviral agents
[6].
Diluted bleach baths are also recommended to help
reduce the number of S. aureus skin infections, and the
need for systemic antibiotics in patients with heavily
colonized skin. Diluted bleach baths involve soaking the
patient for approximately 10 minutes in a tub full of
lukewarm water that is mixed with one-quarter cup (60
mL) of chlorine bleach (this concentration is similar to
the amount of chlorine in a pool). The patient is then
thoroughly rinsed with fresh water, and a moisturizer or
emollient is applied immediately to prevent dehydration
Table 4 Potency of common topical corticosteroid therapies.
Very potent: Moderately potent:
￿ Betamethasone dipropionate (Diprolene) ￿ Clobetasol propionate 0.05% (Dermovate)
￿ Halobetasol propionate (Ultravate)
￿ Halcinonide 0.1% (Halog)
Potent:
￿ Amcinonide 0.1% (Cyclocort)
￿ Betamethasone valerate 0.1% (Betaderm, Celestoderm, Prevex)
￿ Desoximetasone 0.25% (Desoxi, Topicort)
￿ Diflucortolone valerate 0.1% (Nerisone)
￿ Fluocinolone acetonide 0.25% (Derma, Fluoderm, Synalar)
￿ Fluocinonide 0.05% (Lidemol, Lidex, Tiamol, Topsyn)
￿ Fluticasone propionate (Cutivate)
￿ Mometasone furoate 0.1% (Elocom)
￿ Betamethasone valerate 0.05% (Betnovate)
￿ Betamethasone valerate 0.05% (Celestoderm)
￿ Clobetasone butyrate 0.05% (Eumovate)
￿ Hydrocortisone acetate 1.0% (Cortef, Hyderm)
￿ Hydrocortisone valerate 0.2% (Westcort, HydroVal)
￿ Prednicarbate 0.1% (Dermatop)
￿ Triamcinolone acetonide 0.1% (Kenalog, Traiderm)
Mild:
￿ Desonide (Desocort)
￿ Hydrocortisone 0.5% (Cortate, Claritin, Cortoderm)
￿ Hydrocortisone acetate 0.5% (Cortef, Hyderm)
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period of 3 months have been recommended by some
authors [24].
Systemic corticosteroids
Systemic corticosteroids are generally reserved for the
acute treatment of severe AD flare-ups. However, pro-
longed use of oral steroids are associated with well-
known and potentially serious adverse effects and, there-
fore, their long-term use should be avoided. Further-
more, it is important to note that relapses are common
following discontinuation of oral corticosteroid therapy
[6].
Other therapies
Ultraviolet (UV) phototherapy may be beneficial for the
treatment of AD in adults. However, the long-term toxi-
city of UV therapy is still unknown. Other treatment
options are available for severe, refractory AD, such as
cyclosporine A and azathrioprine; however, these thera-
peutic options should be reserved for unique situations
and typically require consultation with an allergist or
dermatologist [6].
Prognosis
The prognosis for patients with AD is generally favour-
able, with most children outgrowing the condition by
early adolescence. However, patients with severe, wide-
spread disease and concomitant atopic conditions, such
as asthma and allergic rhinitis, are likely to experience
poorer outcomes [10].
Conclusions
AD is a common, chronic skin disease that starts early
in life and can adversely impact the quality of life of
patients and their caregivers. Optimal skin care practices
and topical corticosteroids remain the cornerstone of
therapy for the disease. TCIs have been shown to pro-
vide an effective, second-line alternative to topical corti-
costeroids in appropriate patients prone to frequent
flare-ups. Allergy testing to foods and aeroallergens may
be considered based on patient history and/or in
patients exhibiting a poor response to optimal skin care
practices and appropriate pharmacological therapy.
Key take-home messages
￿ AD is the most common skin disorder in children, and
significantly impacts quality of life.
￿ The diagnosis of AD is basedo ns p e c i f i cd i a g n o s t i c
criteria that take into account the patient’sh i s t o r ya n d
clinical manifestations.
￿ Allergy testing using SPTs or serum-specific IgE
measurements may be useful for identifying triggers of
AD if the patient’s history is suggestive of allergies to
foods or other environmental factors; random or screen-
ing allergy tests to foods are not recommended.
￿ Optimal skin care practices and topical corticoster-
oids are the mainstay of therapy for AD.
￿ TCIs are a second-line alternative to topical corti-
costeroids and should be reserved for the intermittent
treatment of immunocompetent patients with moderate
to severe AD.
￿ The skin of most patients with AD is heavily colo-
nized with S. aureus; therefore, topical and/or antibiotic
therapy may be required for overt infections.
￿ First-generation antihistamines may be helpful for
improving sleep in patients with AD.
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